Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cyntellect, a life sciences company focused on new standards in cell analysis, purification, and processing technology, has appointed Saiid Zarrabian as new president and CEO. Mr Zarrabian will replace Fred Koller, who has assumed the position of chief technology officer.
Subscribe to our email newsletter
Cyntellec has said that Mr Zarrabian has been consulting with the company and has been acting CEO since March of 2010.
Previously, he served as president and COO of biotechnology company Synomyx, as COO of Pharmacopeia and COO of Molecular Simulations.
Most recently, he performed executive consulting services to firms including BioBlocks, eMolecules, Invitrogen, and SciTegic, where he served as executive consultant and acting COO until the company was acquired by Accelrys.
Mr Zarrabian currently serves on the board of biopharmaceutical company Ambit Biosciences, and chemistry eCommerce portal, eMolecules.
Mr Koller, co-founder of Cyntellect, said: “Saiid has spent his entire career working to advance scientific innovation and entrepreneurship. His experience and leadership will be invaluable as Cyntellect advances its high value technology and award winning products into our customers’
research and development processes and emerging commercial applications.”
Mr Zarrabian said: “In the past year alone, Cyntellect has expanded dramatically into Europe and Asia, and has commercialized novel new products for applications in cell line development for biopharmaceuticals, drug discovery and cancer research, including key applications utilizing stem cells.
“I am also enthused about our strong collaborations which will help Cyntellect to drive high value solutions based on our LEAP Cell Processing Workstation and Celigo Adherent Cell Cytometer systems.”